Table Graph
      published meta-analysis   sensitivity analysis   studies

chloroquine and derivatives in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsCOPE – Coalition V, 2022 1.56 [0.39; 6.24] COVID-PEP Severity (Skipper), 2020 1.01 [0.06; 16.28] 1.43[0.41; 4.95]COPE – Coalition V, 2022, COVID-PEP Severity (Skipper), 202020%1,860moderatenot evaluable hospitalization or deathdetailed resultsALBERTA HOPE-Covid19, 2021 2.73 [0.14; 52.87] 2.73[0.14; 52.87]ALBERTA HOPE-Covid19, 202110%148NAnot evaluable clinical improvementdetailed resultsCOVID-PEP Severity (Skipper), 2020 1.36 [0.87; 2.11] 1.36[0.87; 2.11]COVID-PEP Severity (Skipper), 202010%395NAnot evaluable clinical improvement (14-day)detailed resultsCOVID-PEP Severity (Skipper), 2020 1.36 [0.87; 2.11] 1.36[0.87; 2.11]COVID-PEP Severity (Skipper), 202010%395NAnot evaluable hospitalizationdetailed resultsCOPE – Coalition V, 2022 0.77 [0.52; 1.13] 0.77[0.52; 1.13]COPE – Coalition V, 202210%1,372NAnot evaluable mechanical ventilationdetailed resultsCOPE – Coalition V, 2022 1.32 [0.46; 3.79] 1.32[0.46; 3.79]COPE – Coalition V, 202210%1,369NAnot evaluable ICU admissiondetailed resultsCOPE – Coalition V, 2022 0.84 [0.43; 1.63] 0.84[0.43; 1.63]COPE – Coalition V, 202210%1,369NAnot evaluable adverse eventsdetailed resultsCOVID-PEP Severity (Skipper), 2020 1.00 [0.02; 50.40] 1.00[0.02; 50.40]COVID-PEP Severity (Skipper), 202010%423NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-04-25 08:11 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 508,656,657,832 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons